Anna Shteingauz Preclinical Research Department Novocure Ltd., Haifa, Israel Biography Publications Institution JoVE Articles Anna Shteingauz has not added a biography. If you are Anna Shteingauz and would like to personalize this page please email our Author Liaison for assistance. Publications Alternating Electric Fields (TTFields) in Combination with Paclitaxel Are Therapeutically Effective Against Ovarian Cancer Cells in Vitro and in Vivo International Journal of Cancer. Dec, 2016 | Pubmed ID: 27561100 Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells Scientific Reports. Dec, 2015 | Pubmed ID: 26658786 Function from Within: Autophagy Induction by HPSE/heparanase--new Possibilities for Intervention Autophagy. 2015 | Pubmed ID: 26571129 Heparanase Enhances Tumor Growth and Chemoresistance by Promoting Autophagy Cancer Research. Sep, 2015 | Pubmed ID: 26249176 Latent Heparanase Facilitates VLA-4-mediated Melanoma Cell Binding and Emerges As a Relevant Target of Heparin in the Interference with Metastatic Progression Seminars in Thrombosis and Hemostasis. Mar, 2015 | Pubmed ID: 25682080 Processing of Heparanase is Mediated by Syndecan-1 Cytoplasmic Domain and Involves Syntenin and α-actinin Cellular and Molecular Life Sciences : CMLS. Nov, 2014 | Pubmed ID: 24788042 Modification of Heparanase Gene Expression in Response to Conditioning and LPS Treatment: Strong Correlation to Rs4693608 SNP Journal of Leukocyte Biology. Apr, 2014 | Pubmed ID: 24319286 Heparanase 2 Interacts with Heparan Sulfate with High Affinity and Inhibits Heparanase Activity The Journal of Biological Chemistry. Sep, 2010 | Pubmed ID: 20576607 The BTB-MATH Protein BATH-42 Interacts with RIC-3 to Regulate Maturation of Nicotinic Acetylcholine Receptors Journal of Cell Science. Mar, 2009 | Pubmed ID: 19223395 Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields (TTFields) Yaara Porat1, Moshe Giladi1, Rosa S. Schneiderman1, Roni Blat1, Anna Shteingauz1, Einav Zeevi1, Mijal Munster1, Tali Voloshin1, Noa Kaynan1, Orna Tal1, Eilon D. Kirson2, Uri Weinberg3, Yoram Palti2 1Preclinical Research Department, Novocure Ltd., Haifa, Israel, 2Novocure Ltd., Haifa, Israel, 3Novocure GmbH, Lucerne, Switzerland JoVE 55820 Cancer Research
Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields (TTFields) Yaara Porat1, Moshe Giladi1, Rosa S. Schneiderman1, Roni Blat1, Anna Shteingauz1, Einav Zeevi1, Mijal Munster1, Tali Voloshin1, Noa Kaynan1, Orna Tal1, Eilon D. Kirson2, Uri Weinberg3, Yoram Palti2 1Preclinical Research Department, Novocure Ltd., Haifa, Israel, 2Novocure Ltd., Haifa, Israel, 3Novocure GmbH, Lucerne, Switzerland JoVE 55820 Cancer Research
